NCT02951325 (BART) is a Phase 3 clinical trial of Adjuvant RT in Bladder Cancer, sponsored by Tata Memorial Centre.

Who is sponsoring NCT02951325?

NCT02951325 is sponsored by Tata Memorial Centre.

What drugs are being tested in NCT02951325?

Interventions in NCT02951325: Adjuvant RT.

What condition does NCT02951325 study?

NCT02951325 studies Bladder Cancer, Urothelial Carcinoma Bladder.

Is NCT02951325 still recruiting?

NCT02951325 is currently active, enrolled. Last updated 13 February 2025.

Last reviewed 2025-02-13 · How we verify

NCT02951325: BART

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bladder Cancer Adjuvant Radiotherapy Trial

Active, enrolled Phase 3 Last updated 13 February 2025

What this trial tests

Phase 3 trial testing Adjuvant RT in Bladder Cancer in 153 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

2 June 2016

Primary endpoint
8 May 2024

13 April 2030

Quick facts

Lead sponsor	Tata Memorial Centre
Phase	Phase 3
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	153
Start date	2 June 2016
Primary completion	8 May 2024
Estimated completion	13 April 2030
Sites	1 location across India

Drugs / interventions tested

Adjuvant RT

Conditions studied

Bladder Cancer — all drugs for Bladder Cancer →
Urothelial Carcinoma Bladder — all drugs for Urothelial Carcinoma Bladder →

Sponsor

Tata Memorial Centre — full company profile →

Who can join

18 and older, any sex, with Bladder Cancer or Urothelial Carcinoma Bladder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Aim and objectives: This trial aims to evaluate the role of adjuvant radiotherapy following chemotherapy in patients with high-risk features on histo-pathology after radical surgery for transitional cell carcinoma of urinary bladder

Publications & conference data

6 peer-reviewed publications reference this trial (live from Europe PMC):

Risk factors for loco-regional recurrence after radical cystectomy of muscle-invasive bladder cancer: A systematic-review and framework for adjuvant radiotherapy.
Sargos P, Baumann BC, Eapen L, Christodouleas J, et al · · 2018 · cited 34× · PMID 30125800 · DOI 10.1016/j.ctrv.2018.07.011
Trimodality therapy for bladder cancer: modern management and future directions.
Pham A, Ballas LK. · · 2019 · cited 32× · PMID 30855374 · DOI 10.1097/mou.0000000000000601
The Rationale for Post-Operative Radiation in Localized Bladder Cancer.
Baumann BC, Sargos P, Eapen LJ, Efstathiou JA, et al · · 2017 · cited 22× · PMID 28149931 · DOI 10.3233/blc-160081
Radiotherapy Use in Muscle-Invasive Bladder Cancer: Review of the Guidelines and Impact of Increased Awareness in Patient Referral at a Tertiary Center in Belgium.
Verghote F, Van Praet C, De Maeseneer D, Berquin C, et al · · 2023 · cited 6× · PMID 37337479 · DOI 10.2147/cmar.s407031
Bone Marrow Suppression during Postoperative Radiation for Bladder Cancer and Comparative Benefit of Proton Therapy-Phase 2 Trial Secondary Analysis.
Press RH, Shelton JW, Zhang C, Dang Q, et al · · 2022 · cited 6× · PMID 35127970 · DOI 10.14338/ijpt-21-00003.1
Radiotherapy with radical cystectomy for bladder cancer: A systematic review and meta-analysis.
Mcalpine K, Fergusson DA, Breau RH, Reynolds LF, et al · · 2018 · cited 5× · PMID 29989916 · DOI 10.5489/cuaj.5244

Verify or expand the search:

Other trials of Adjuvant RT

Trials testing the same drug.

NCT03107182 — Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer · Phase 2 · completed

Other recruiting trials for Bladder Cancer

Currently open trials in the same condition.

NCT07419295 — A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) · Phase 3 · recruiting
NCT07322263 — Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC · Phase 2 · recruiting
NCT07420517 — Dutasteride in Patients With Low Grade Non-muscle Invasive Bladder Cancer · Phase 2 · recruiting
NCT07475403 — Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer · Phase 2 · recruiting
NCT07277413 — A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors · Phase 1 · recruiting

Other Tata Memorial Centre trials

Trials by the same sponsor.

NCT07236840 — Self-administered Remote Neurological Examination Using Mobile Application in Patients With Brain Tumors · recruiting
NCT06492486 — Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow · Phase 2 · not yet recruiting
NCT07338539 — BIO-SHORT: Biologically Guided Short-Course Hypofractionated RT for Poor-Prognosis GBM · Phase 2 · recruiting
NCT07395635 — Phase II Trial of Immunonutrition in Hepatectomy · NA · recruiting
NCT07338526 — Intensity Modulated PrOton Therapy in Pediatric BRain Tumors (IMPORT) · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02951325 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tata Memorial Centre
Last refreshed: 13 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02951325.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing